Advertisement
| biologic therapy for ankylosing spondylitis: Axial Spondyloarthritis Stefan Siebert, Raj Sengupta, Alexander Tsoukas, 2016 A practical pocketbook for the nonspecialist practitioner, Axial Spondyloarthritis is the essential guide to the commonest inflammatory arthritis affecting the spine. Focusing on the practical implications of developments in classification, diagnosis, and treatment, this easily accessible text fully covers the broader spectrum of this condition. |
| biologic therapy for ankylosing spondylitis: Mesenchymal Stem Cell Therapy Lucas G. Chase, Mohan C Vemuri, 2012-12-12 Over the past decade, significant efforts have been made to develop stem cell-based therapies for difficult to treat diseases. Multipotent mesenchymal stromal cells, also referred to as mesenchymal stem cells (MSCs), appear to hold great promise in regards to a regenerative cell-based therapy for the treatment of these diseases. Currently, more than 200 clinical trials are underway worldwide exploring the use of MSCs for the treatment of a wide range of disorders including bone, cartilage and tendon damage, myocardial infarction, graft-versus-host disease, Crohn’s disease, diabetes, multiple sclerosis, critical limb ischemia and many others. MSCs were first identified by Friendenstein and colleagues as an adherent stromal cell population within the bone marrow with the ability to form clonogenic colonies in vitro. In regards to the basic biology associated with MSCs, there has been tremendous progress towards understanding this cell population’s phenotype and function from a range of tissue sources. Despite enormous progress and an overall increased understanding of MSCs at the molecular and cellular level, several critical questions remain to be answered in regards to the use of these cells in therapeutic applications. Clinically, both autologous and allogenic approaches for the transplantation of MSCs are being explored. Several of the processing steps needed for the clinical application of MSCs, including isolation from various tissues, scalable in vitro expansion, cell banking, dose preparation, quality control parameters, delivery methods and numerous others are being extensively studied. Despite a significant number of ongoing clinical trials, none of the current therapeutic approaches have, at this point, become a standard of care treatment. Although exceptionally promising, the clinical translation of MSC-based therapies is still a work in progress. The extensive number of ongoing clinical trials is expected to provide a clearer path forward for the realization and implementation of MSCs in regenerative medicine. Towards this end, reviews of current clinical trial results and discussions of relevant topics association with the clinical application of MSCs are compiled in this book from some of the leading researchers in this exciting and rapidly advancing field. Although not absolutely all-inclusive, we hope the chapters within this book can promote and enable a better understanding of the translation of MSCs from bench-to-bedside and inspire researchers to further explore this promising and quickly evolving field. |
| biologic therapy for ankylosing spondylitis: Axial Spondyloarthritis Philip Mease, Muhammad Asim Khan, 2019-02-16 Focusing on the key essentials you need to know, Axial Spondyloarthritis provides a quick, expert overview of axSpA from a clinical perspective. This concise resource by Drs. Philip Mease and Muhammad Khan presents practical recommendations and guidelines for the diagnosis, management, and treatment of spondyloarthritis impacting the axial skeleton alongside an overview of epidemiology, special populations, and patient education. - Discusses key information on genetic factors and disease biomarkers. - Presents an overview of clinical features, classification criteria, and imaging to aid in diagnosis. - Covers management and treatment guidelines, including non-pharmacologic management and the use of biologics. - Consolidates essential information on this timely topic into a single, convenient resource. |
| biologic therapy for ankylosing spondylitis: Biologics in General Medicine W.-H. Boehncke, H.H. Radeke, 2007-05-08 This is the first book to cover every angle in the clinical application of biologics. Readers will not only find that all of the biologics currently approved for clinical use are delineated in a standardized way, but also the differential therapy with biologics in fields including dermatology and neurology is described in detail and summarized in treatment algorithms. Shorter sections on biologic biotechnology as well as safety and regulatory issues complement the more clinically-oriented central chapters. |
| biologic therapy for ankylosing spondylitis: Ankylosing Spondylitis Joachim Sieper, Jurgen Braun, 2010-11-25 Ankylosing Spondylitis in Clinical Practice is a concise, practical guide on the diagnosis and management of this debilitating condition. This book is aimed at clinicians who treat Ankylosing Spondylitis. It provides an authoritative, accessible guide to the diagnosis, management and treatment of ankylosing spondylitis. |
| biologic therapy for ankylosing spondylitis: Safety of Biologics Therapy Brian A. Baldo, 2016-08-12 This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences. |
| biologic therapy for ankylosing spondylitis: Uveitis George N. Papaliodis, 2017-02-03 Written as a practical guide for the diagnosis and treatment of uveitis, this text provides uveitis specialists, practicing ophthalmologists, ophthalmology residents and fellows with the appropriate diagnostic testing and evidenced-based therapeutic options for managing patients afflicted with these conditions. Written and edited by leaders in the fields of ophthalmology, rheumatology, internal medicine, infectious disease, and oncology, each chapter addresses the latest advances in the field: from the advent of PCR technology, intraocular depot steroid implants, neoplastic and infectious diseases masquerading as uveitis, and the use of systemic immunomoduatory therapies (including biologic agents/humanized monoclonal antibodies). |
| biologic therapy for ankylosing spondylitis: The Handbook of Biological Therapy Bruce Kirkham, Arthur Kavanaugh, Scott Eric Plevy, Jonathan Barker, 2008-11-27 Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted for the likes of rituximab, abatacept and certocizumals pegol. Intensive research is also defining new areas in which these drugs will be used in the future, increasing the number of practitioners using biologics. As the use of these drugs increases around the world, so the level of information needed by primary care practitioners and specialist prescribers needs to be expanded The Handbook of Biological Therapy provides the practising clinician with a practica guide to the use of Tumour Necrosis Factor Blocking Therapy (TNF-blockers), and important new class of biologic therapy for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis. It is a comprehensive distillation of the authors' clinical experience with these drugs, combined with data from diverse databases offering practical advice on their uses, specific indications, supporting clinical trial data and safety issues, with the aim of making the use of these drugs easier for the busy clinician. All of the authors have been involved from the beginnings of the clinical trial programmes with these drugs and continue to use them in daily practice. |
| biologic therapy for ankylosing spondylitis: Rheumatology and Immunology Alan S. Cohen, J. Claude Bennett, 1986 |
| biologic therapy for ankylosing spondylitis: Mosaic of Autoimmunity Carlo Perricone, Yehuda Shoenfeld, 2019-02-13 The Mosaic of Autoimmunity: The Novel Factors of Autoimmune Diseases describes the multifactorial origin and diversity of expression of autoimmune diseases in humans. The term implies that different combinations of factors in autoimmunity produce varying and unique clinical pictures in a wide spectrum of autoimmune diseases. Most of the factors involved in autoimmunity can be categorized into four groups: genetic, immune defects, hormonal and environmental factors. In this book, the environmental factors are reviewed, including infectious agents, vaccines as triggers of autoimmunity, smoking and its relationship with rheumatoid arthritis, systemic lupus erythematosus, thyroid disease, multiple sclerosis and inflammatory bowel diseases. An entirely new syndrome, the autoimmune/inflammatory syndrome induced by adjuvants (ASIA), is also included, along with other diseases that are now recognized as having an autoimmune etiopathogenesis. |
| biologic therapy for ankylosing spondylitis: Moderate to Severe Psoriasis John Koo, Jashin Wu, Alice Gottlieb, Ethan Levin, Argentina Leon, 2014-03-18 Written by experts in the dermatology field, this new fourth edition of Moderate-to-Severe Psoriasis discusses the current use of biologics and other pharmacologic and phototherapy treatments for moderate-to-severe psoriasis. Illustrated with high quality color figures, this standalone text emphasizes safe and effective treatments for the psoriasis |
| biologic therapy for ankylosing spondylitis: Biologics, Biosimilars, and Biobetters Iqbal Ramzan, 2021-02-03 A comprehensive primer and reference, this book provides pharmacists and health practitioners the relevant science and policy concepts behind biologics, biosimilars, and biobetters from a practical and clinical perspective. Explains what pharmacists need to discuss the equivalence, efficacy, safety, and risks of biosimilars with physicians, health practitioners, and patients about Guides regulators on pragmatic approaches to dealing with these drugs in the context of rapidly evolving scientific and clinical evidence Balances scientific information on complex drugs with practical information, such as a checklist for pharmacists |
| biologic therapy for ankylosing spondylitis: Therapy for Severe Psoriasis E-Book Jashin J. Wu, Steven R. Feldman, Mark Lebwohl, 2016-12-02 A brand-new title in the field of dermatology, Therapy for Severe Psoriasis provides the ultimate coverage of the treatment options available for today's most serious cases, including biologics and oral therapies. It features discussions of the newest drug therapies, recent FDA-approved biosimilars, and combination approaches to care, while an overview chapter was designed to aid those new to the field in understanding the nuances of difficult-to-treat subtypes of psoriasis. Comprehensive and focused, Therapy for Severe Psoriasis will be a welcome addition to the library of any dermatologist seeking in-depth information on the challenges of this condition. - Each of the 16 chapters includes either an in-depth focus on a single therapy or an overview of a unique aspect of psoriasis, including: UVB therapy, methotrexate, acitretin, cyclosporine, apremilast, etanercept, infliximab, adalimumab, ustekinumab, secukinumab, and ixekizumab. - Takes an evidence-based approach to hard-to-treat severe psoriasis. - Discusses the newest drug therapies (such as ixekizumab), plus recent FDA-approved biosimilars, a topic unique to this particular psoriasis text. - Presents combination approaches for instances when standard treatments are not successful. - Includes an overview chapter to help beginners understand the nuances of the disorder. |
| biologic therapy for ankylosing spondylitis: Adverse Reactions to Biologics L. Puig, W. Gulliver, 2017-11-07 In many areas of medicine physicians still face the great challenge of finding therapies that will meet the patients’ needs. In dermatology the challenge has arisen on multiple fronts through advances in the understanding of the immunopathogenesis of many inflammatory and malignant cutaneous disorders. Breakthroughs, combined with significant developments in targeted immunotherapy, have resulted in improved outcomes as these newer therapies are being used for both approved indications and as off-label therapies for various chronic inflammatory skin disorders and many forms of skin cancer. In the expectation that by truly understanding the safety profile of these targeted therapies patients’ outcomes will be significantly improved, this book offers insights into topics such as adverse reactions, infectious complications and the perioperative use of biologics in psoriasis, immunogenicity of biologic therapies, paradoxical reactions, safety of biologics used to treat autoimmune bullous diseases and primary cutaneous lymphomas, adverse reactions and skin manifestations of therapies targeting melanoma and non-melanoma skin cancer and other neoplastic diseases. Eminent researchers with extensive clinical experience have contributed to this publication, providing an in-depth overview of the latest knowledge in this field. |
| biologic therapy for ankylosing spondylitis: Tuberculosis National Collaborating Centre for Chronic Conditions (Great Britain), Royal College of Physicians of London, 2006 |
| biologic therapy for ankylosing spondylitis: Biologic Therapies of Immunologic Diseases, An Issue of Immunology and Allergy Clinics of North America Bradley E. Chipps, Stephen P. Peters, 2017-04-12 This issue of Immunology and Allergy Clinics, guest edited by Drs. Bradley Chipps and Stephen Peters, is devoted to Biologic Therapies of Immunologic Diseases. Articles in this issue include: Immunologic Mechanisms and Potential Targets; Strategies for Immunologic Interventions; Patient Characteristics and Individualization of Therapy; Biologic Therapies for Autoimmune and Connective Tissue Diseases; Biologic Therapies for Skin Disease including Urticaria; Biologic Therapies for Asthma; Biologic Therapies for Rhinitis and Sinusitis; Biologic Therapies for Chronic Obstructive Pulmonary Disease; Biologic Therapies for Food Allergies and Eosinophilic Esophagitis; Future Prospects for Biologic Therapies of Immunologic Diseases; Pharmacoeconomics of Biologic Therapy; and Adverse Reaction to Biologic Therapy. |
| biologic therapy for ankylosing spondylitis: Pediatric Rheumatology, an Issue of Rheumatic Disease Clinics Andreas Reiff, 2013-11-12 This issue of Rheumatic Disease Clinics teaches you the latest developments and best practices in pediatric rheumatology. Guest edited by Andreas Reiff, topics include juvenile arthritis, juvenile spondyloarthritis, inflammatory bowel disease, vasculitis, scleroderma, eye conditions, and more |
| biologic therapy for ankylosing spondylitis: Treatment of Non-infectious Uveitis Phoebe Lin, Eric Suhler, 2019-09-12 This unique, comprehensive book provides a much-needed reference on the treatment and management of non-infectious uveitis. Carefully designed, Treatment of Non-infectious Uveitis is the first book of its kind to provide an in-depth, clinically-relevant, expert-driven resource for ophthalmologists focusing on modalities of uveitis treatment, their mechanism of action, dosing, and side effects. Each chapter provides an introduction, mechanism of action, indication, dosage, side effects, and efficacy summaries from clinical trials and other published literature. Topics range from topical treatment, to locally administered therapy including drug-releasing implants, to systemic immunosuppressive treatments both tried and new, as well as surgical management, with each chapter highlighting important practice pearls as well as easy-reference dosing tables, side effects, and lab monitoring pertinent to the agents discussed. The book concludes with a discussion of novel approaches to the treatment of non-infectious uveitis, and special considerations when treating uveitis in the pediatric patient. The majority of patients with non-infectious uveitis are treated by comprehensive ophthalmologists, many of whom are less familiar with established treatment guidelines outlining the role of corticosteroids and immunomodulatory therapy. While the non-specialist, resident, or fellow is sure to benefit from this one-stop guide to uveitis treatment, retina and uveitis specialists alike will also appreciate the practice tips and thorough coverage of this expertly-written reference. Treatment of Non-infectious Uveitis is the ideal reference for all ophthalmologists who seek to improve their understanding of the causes of uveitis and learn how to best treat this condition. |
| biologic therapy for ankylosing spondylitis: TNF Pathophysiology George Kollias, Petros P. Sfikakis, 2010-01-01 TNF is a multifunctional proinflammatory cytokine central to the development and homeostasis of the immune system and a regulator of cell activation, differentiation and death. Recent decades have seen an enormous scientific and clinical interest in the function of TNF in physiology and disease. A vast amount of data has been accumulated at the biochemical, molecular and cellular level, establishing TNF as a prototype for in-depth understanding of the physiological and pathogenic functions of cytokines. This volume covers several current aspects of TNF regulation and function, including transcriptional and posttranscriptional control mechanisms, cellular modes of action, signaling networks that mediate its effect, involvement in pathogenesis and clinical outcomes of TNF antagonists. It combines basic science at the molecular and cellular level with research in animal models of disease and clinical findings to provide a comprehensive review of recent developments in TNF biology. A thorough understanding of the mechanisms by which this key molecular player is produced and functions to regulate cell biology, immunity and disease postulates novel paradigms on how genes contribute to the development and physiology of biological systems. |
| biologic therapy for ankylosing spondylitis: Arthritis Without Pain Scott J. Zashin, M. Laurette Hesser, 2004 The Long-Awaited Breakthrough for Arthritis Pain The miracle of TNF blockers is this: they work. Nearly two of every three patients who try these medications get lasting relief from joint pain and inflammation. Known as biologic DMARDs, these high-tech drugs inhibit the action of tumor necrosis factor (TNF), a protein that contributes to joint damage associated with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Arthritis Without Pain examines the science behind the TNF blockers Enbrel(R), Remicade(R) and HumiraT, offers practical advice for their use, and explores the real-life experience of patients who take them. Written by noted Dallas rheumatologist Scott J. Zashin, M.D., in collaboration with healthcare writer Laurie Hesser, Arthritis Without Pain gives patients the knowledge to take charge of their arthritis, move past the pain, and get back to a more active life. . Learn about TNF blockers and how they work . Compare TNF blockers with methotrexate and other arthritis drugs . Take a 5-minute self-test to see if you are a candidate for anti-TNF therapy . Understand the differences between Enbrel(R), Remicade(R) and HumiraT . Know what to ask before therapy and what to expect during therapy . Gain insight into how biologic drugs are manufactured and why they need special handling . Learn how uninsured/underinsured patients may still have access to these medications . Get tips on living with and traveling with TNF blockers . Read about other patients' experience with these life-changing drugs With the latest information on types of arthritis, standard treatments, lab tests and clinical trials, Arthritis Without Pain is a comprehensive guide to TNF blockers and the state of arthritis treatment today. |
| biologic therapy for ankylosing spondylitis: Endoscopy in Inflammatory Bowel Disease Richard Kozarek, Michael Chiorean, Michael Wallace, 2014-11-03 This book conjoins the latest advances on the use of endoscopy to diagnose, monitor, and treat patients with inflammatory bowel disease. Chapters include the historical use of rigid sigmoidoscopy, non-interventional imaging procedures, and the correlation of pathology and endoscopic visualization. This is the first book to include individual chapters in gastroenterology, colorectal surgery, and IBD texts, the preeminent role of endoscopic imaging in the management of chronic ulcerative colitis, and Crohn's disease. It also includes chapters on capsule endoscopy and balloon and overtube-assisted enteroscopy to define the presence and activity of Crohn's enteritis and additional chapters defining the use of random biopsies versus chromoendoscopy, and computer enhanced imaging to define possible dysplasia development. The book also includes access to online videos, making it the ultimate verbal and visual tool for all medical professionals interested in the advances in the field over the last several decades. Endoscopy in Inflammatory Bowel Disease is a concise text that is of great value to practicing endoscopists, gastroenterologists, general or colorectal surgeons, physicians in training, and all medical professionals caring for patients with inflammatory bowel disease. |
| biologic therapy for ankylosing spondylitis: The Handbook of Biological Therapy Bruce Kirkham, 2008-11-27 Tumor Necrosis Factor (TNF) blocking therapy has recently been introduced as an important new class of biologic therapy for rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, psoriasis and psoriatic arthritis. This class of drugs, currently comprised of three different agents, is being increasingly used for these around the world. Intensive clinical research is also defining new areas in which these drugs will be used in the future. These new indications for TNF-blocking therapy will increase the number of physicians using this class of drug. This guide provides a comprehensive distillation of the clinical experience with these drugs combined with the diverse available databases to provide practical information about the use of these drugs in daily practice. Much of the literature currently available has come from the clinical trial setting with an academic emphasis. This book is rigorously practical and is the guide that every physician including all rheumatologists, and gastroenterologists and dermatologists who treat patients with this class of drugs, will want to have on hand to answer their questions that arise every day. |
| biologic therapy for ankylosing spondylitis: Skills in Rheumatology Hani Almoallim, Mohamed Cheikh, 2021-01-05 This Open Access book presents practical approaches to managing patients affected by various rheumatological diseases, allowing readers to gain a better understanding of the various clinical expressions and problems experienced by these patients. Discussing rheumatology from an organ systems perspective, it highlights the importance ofdetailed musculoskeletal examinations when treating patients affected by rheumatological diseases. The book first explores the latest diagnostic approaches and offers key tips for accurate musculoskeletal examinations before addressing the various treatment modalities, with a particular focus on the most common joints involved in rheumatoid arthritis: the wrists and the metacarpophalangeal joints (2nd and 3rd). Featuring easy-to-understand flow diagrams and explaining the common medical problems associated with rheumatic disease, such as shortness of breath and anemia, it is not only a valuable resource to rheumatologists, but will also appeal to medical students, junior residents, and primary healthcare physicians. |
| biologic therapy for ankylosing spondylitis: Immunogenicity of Proteins Used as Therapeutics Amy Rosenberg, Zuben E. Sauna, Bernard Maillere, Susan Richards, Elizabeth C. Jury, 2020-12-28 Topic Editor Susan Richards is an employee of Sanofi and owns stock in the corporation. Topic Editor Bernard Maillere declares economic support from pharmaceutical companies (Novartis, Sanofi, and UCB) in the frame of collaborations aiming to evaluate the recognition by human T cells of therapeutic proteins and antibodies. |
| biologic therapy for ankylosing spondylitis: Tidy's Physiotherapy Stuart B. Porter, 2008 For the first time the textbook includes a DVD ROM containing sections on musculoskeletal tests, massage and exercises, as well as high resolution graphics that can be used to aid revision, student presentations and teaching purposes. |
| biologic therapy for ankylosing spondylitis: Ankylosing Spondylitis Muhammad Asim Khan, 2009-06-15 Ankylosing Spondylitis (AS) and related diseases called spondyloarthropathies (SpA) are the second most common form of chronic inflammatory arthritis after Rheumatoid Arthritis (RA). Unfortunately, most patients with AS and SpA are either never diagnosed, or they are inadequately treated. The current mean delay in the diagnosis of AS ranges from 5 to 10 years, and the presenting clinical manifestations of these diseases are wide-ranging and heterogeneous, and thus a variety of health care professionals see AS and SpA patients, from primary care physicians to rheumatologists and other medical and surgical specialists. With the availability of newer, highly effective treatments and better methods of musculoskeletal imaging, such as the MRI, there is an urgent need to improve early diagnosis and reduce any inappropriate delay in obtaining effective treatment. Earlier diagnosis and treatment can mitigate the severity of the disease, and make a meaningful difference for patient care and quality of life. The proposed book is designed for specialists and generalists alike, and is intenteded to expedite accurate diagnosis and initiation of appropriate treatment in order to alleviate unnecessary suffering. Part of the new Oxford American Rheumatology Library series, this pocket-sized book provides practical, evidence-based information for clinicians to aid diagnosis, treatment, and follow-up care for patients with AS and SpA. The book provides pointers to early diagnosis, prognosis, clinical manifestations, socioeconomic aspects, and disease management. It also provides comprehensive coverage of current treatment options, including the latest biologics, as well as non-drug therapies. |
| biologic therapy for ankylosing spondylitis: Obstetric Medicine Catherine Nelson-Piercy, Joanna Girling, 2007-05-26 Recognition of the importance of maternal medicine is now reflected in the content of the MRCOG exam, core training and higher training in both obstetrics and medicine. This book approaches obstetric medicine from the point of view of real patients and clinical scenarios as well as model answers to exam questions. The book will be invaluable for trainees and consultants who want to ‘test themselves’. |
| biologic therapy for ankylosing spondylitis: Clinical and Molecular Advances in Ankylosing Spondylitis Jacome Bruges-Armas, 2012-02-22 The first section of the book entitled Clinical and Molecular Advances in Ankylosing Spondylitis is a review of the clinical manifestations of Ankylosing Spondylitis (AS) and Spondyloarthritis (SpA). The book includes chapters on Bone Mineral Density measurements, two chapters on the temporomandibular joints, axial fractures, clinical manifestations, diagnosis, and treatment. Molecular genetics and immune response are analyzed in the second section of the book; information on HLA-B*27, other MHC genes and the immune response of AS patients to bacteria is reviewed and updated. Two chapters are dedicated to recent information on non-MHC genes in AS susceptibility, and to new data on disease pathways generated from gene expression studies on peripheral blood. |
| biologic therapy for ankylosing spondylitis: The Spondylarthritides Andrei Calin, Joel D. Taurog, 2023 The Spondylarthritides provides up-to-date, in-depth reviews of the current state of knowledge of the genetic, epidemiologic, microbiologic, and immunologic aspects of these disorders. |
| biologic therapy for ankylosing spondylitis: Nutrition Guide for Clinicians Neal D. Barnard, Rick Weissinger, MS, Brent J. Jaster, MD, 2009 Designed by medical professionals, this manual is a comprehensive, portable medical reference that covers nearly one hundred diseases and conditions, including risk factors, diagnoses, and typical treatments. Most importantly, it provides the latest evidence-based information on nutrition's role in prevention and treatment. |
| biologic therapy for ankylosing spondylitis: Ankylosing spondylitis and Klebsiella Alan Ebringer, 2012-11-08 Ankylosing spondylitis and Klebsiella is a comprehensive and informative text on the cause of Ankylosing spondylitis. Ankylosing spondylitis (AS) is a condition which affects 20 million people worldwide and is likely caused or initiated by a bowel infection from Klebsiella bacteria. When a patient is infected by Klebsiella bacteria, his or her immune system will make antibodies against all the antigens or molecules found in the microbe. Because some of the bacterial antigens resemble self tissues, the anti-bacterial antibodies will attack not only the bacteria but also the self tissues such as the joints and the cells having the same HLA molecules, which is how the disease AS starts. This is the concept of molecular similarity or “molecular mimicry” which previously has been found to work in two other autoimmune diseases; rheumatic fever and rheumatoid arthritis. The first paper on this subject was published in 1976 and since then over 100 papers on rheumatological topics have been published, from Prof Ebringer’s group, at the Division of Life Sciences, King’s College in London, UK. The relevant information from these papers is extracted and presented in this book format making it accessible to health professionals, research institutions, pharmaceutical companies and universities and the general public. |
| biologic therapy for ankylosing spondylitis: Molecular Mechanisms of Spondyloarthropathies Carlos López-Larrea, Roberto Díaz-Peña, 2009-06-25 It is now over ten years since we edited the first edition of HLA-B27 in the Development of Spondyloarthropathies (SpA). It is obvious that over this period an enormous amount of information concerning SpA and HLA-B27 has accumulated, and this has been reflected in the knowledge of molecular mechanism of the spondyloarthropathies. Discussion for such a book took initial form at the outstanding 4th Gent Symposium on SpA in October 2006, but was not formally commissioned by Landes Bioscience until early 2007. Molecular Mechanisms of Spondyloarthropathies aims to synthesize this growing knowledge and present all the current studies concerning the basic research of SpA. Over the last decade, enormous progress has been made in the understanding of the molecular and cellular processes that lead to disease pathology. Recognition of the pathways involved in the pathogenic mechanisms of disease and the potential to target specific immune effector functions have opened the door to a wide range of innovative treatment opportunities for the SpA. Thus, we believe that the understanding of the specific molecular mechanisms involved would help to design highly specific drugs in the future. The contributors are among the best in their field and reflect the state of the art of research and current opinion of rheumatologists and immunologists. |
| biologic therapy for ankylosing spondylitis: Biologics and Biosimilars Xiaodong Feng, Hong-Guang Xie, Ashim Malhotra, Catherine F. Yang, 2022-06-13 Biologics and Biosimilars: Drug Discovery and Clinical Applications is a systematic integration and evaluation of all aspects of biologics and biosimilars, encompassing research and development, clinical use, global regulation, and more. Biosimilars are biological therapeutic agents designed to imitate a reference biologic with high similarities in structure, efficacy, and safety, but also with potential clinical effective and cost-efficient options for the manufacturers, payers, clinicians, and patients. Most of the top-selling prescription drugs in the current market are biologics, which have revolutionized the treatment strategies and modalities for life-threatening and/or rare diseases. This book outlines the key processes and challenges in drug development, regulations, and clinical applications of biologics, biosimilars, and even interchangeable biosimilars. Global experts in the field discuss essential categories and prototype drugs of biologics and biosimilars in clinical practice such as allergenics, blood and blood components, cell treatment, gene therapy, recombinant therapeutic proteins or peptides, tissues, and vaccines. Additional features: Integrates the latest bench and bedside evidence of drug development and regulations of biologics and biosimilars Contains key study questions for each chapter to guide the readers, as well as drug charts for all therapeutic applications of biologics and biosimilars Presents detailed schematic illustrations to explain the drug development, clinical trials, regulations, and clinical applications of biologics and biosimilars This book is an invaluable tool for health care professional students, providers, and pharmaceutical and health care industries, as well as the public, providing readers with educational updates about the drug development and clinical affairs of biological medications and their similar drugs. |
| biologic therapy for ankylosing spondylitis: DECODING MEDICINE PARTHA PRATIM KALITA, 2019-07-19 The human body is a confluence of systems where each system works in a co-operative way. So when it comes to medical education, a vast difference is seen between the academic classroom knowledge and the practical application of that knowledge, where tough and unique decisions have to be taken, keeping in mind the various interactions and side effects of the prescribed treatment. Such knowledge comes through various research activities, practical experience and patient follow up. This book in a unique compilation of all such practical situations where years of experience, to-the-point decisions and lots of background knowledge matters. Decoding Medicine is the definitive guide for anyone involved in patient care or pursuing medicine as their career. |
| biologic therapy for ankylosing spondylitis: Global Tuberculosis Report 2017 World Health Organization, 2017-12-13 WHO's Global Tuberculosis Report provides a comprehensive and up-to-date assessment of the TB epidemic and of progress in care and prevention at global, regional and country levels. This is done in the context of recommended global TB strategies and associated targets, and broader development goals. For the period 2016-2035, these are WHO's End TB Strategy and the United Nations' (UN) Sustainable Development Goals (SDGs), which share a common aim: to end the global TB epidemic. The main data sources for the report are annual rounds of global TB data collection implemented by WHO's Global TB Program since 1995 and databases maintained by other WHO departments, UNAIDS and the World Bank. In WHO's 2017 round of global TB data collection, 201 countries and territories that account for over 99% of the world's population and TB cases reported data. |
| biologic therapy for ankylosing spondylitis: Infections and the Rheumatic Diseases Luis R. Espinoza, 2020-10-23 This book provides a comprehensive and up-to-date review of the basic and clinical aspects of infections and infectious processes that trigger or aggravate a variety of autoimmune and inflammatory musculoskeletal disorders. It delivers a timely update on the interactions between infection and rheumatic diseases in order to provide clinicians with the tools they need for proper diagnosis and treatment. The book is divided into five main sections. The first examines the basic aspects of bacterial infections with a discussion of molecular biology, the microbiome, various types of bacteria that cause infection, and recent advances in biologic therapy. The next section focuses on different forms of viral arthritis including hepatitis arthritis, arthritis associated with alpha viruses, and parvovirus-related arthritis. Subsequent chapters then discuss arthritis caused by mycobacteria, fungi, spirochete, and other miscellaneous arthritides. Following this are various analyzations on reactive arthritis and infection-related rheumatic diseases such as Whipple’s Disease, SAPHO Syndrome, rheumatic fever, and HIV-associated rheumatic manifestations. Finally, the book closes with three chapters on external impacts on infectious diseases such as climate change, vaccinations and systemic lupus erythematosus. Infections and the Rheumatic Diseases is an essential resource for physicians and related professionals, residents, fellows, graduate students, and nurses in rheumatology, clinical immunology, and internal medicine. |
| biologic therapy for ankylosing spondylitis: Biological Drugs Amit Sengupta, 2018 |
| biologic therapy for ankylosing spondylitis: Biologic and Systemic Agents in Dermatology Paul S. Yamauchi, 2018-01-02 Written by leading experts in the field and designed for dermatologists and residents, this book includes evidence-based medicine that underscores the clinical data, as well as practical tips on how to use both biologic and systemic agents in the field of dermatology. In the past decade, there have been several groundbreaking advances in medical dermatology. Novel biologic and systemic agents have been developed to treat inflammatory disorders, including psoriasis and atopic dermatitis, as well as skin malignancies such as melanoma. Biologic and Systemic Agents in Dermatology encompasses these developments by describing the mechanism of action of these various agents and the clinical efficacy and safety to treating these respective disorders. The utilization of biologic and systemic agents in other dermatologic conditions, pharmacoeconomics, pharmacovigilance, and clinical trials outcomes are discussed as well as topics including tumor necrosis, conventional systemic agents for psoriatic disease, and oral agents for atopic dermatitis. |
| biologic therapy for ankylosing spondylitis: Biological Drug Products Wei Wang, Manmohan Singh, 2013-08-29 Tested and proven solutions to the challenges of biological drug product development Biological drug products play a central role in combating human diseases; however, developing new successful biological drugs presents many challenges, including labor intensive production processes, tighter regulatory controls, and increased market competition. This book reviews the current state of the science, offering readers a single resource that sets forth the fundamentals as well as tested and proven development strategies for biological drugs. Moreover, the book prepares readers for the challenges that typically arise during drug development, offering straightforward solutions to improve their ability to pass through all the regulatory hurdles and deliver new drug products to the market. Biological Drug Products begins with general considerations for the development of any biological drug product and then explores the strategies and challenges involved in the development of specific types of biologics. Divided into five parts, the book examines: Part 1: General Aspects Part 2: Proteins and Peptides Part 3: Vaccines Part 4: Novel Biologics Part 5: Product Administration/Delivery Each chapter has been prepared by one or more leading experts in biological drug development. Contributions are based on a comprehensive review and analysis of the current literature as well as the authors' first-hand experience developing and testing new drugs. References at the end of each chapter serve as a gateway to original research papers and reviews in the field. By incorporating lessons learned and future directions for research, Biological Drug Products enables pharmaceutical scientists and students to improve their success rate in developing new biologics to treat a broad range of human diseases. |
| biologic therapy for ankylosing spondylitis: Treatment of Inflammatory Bowel Disease with Biologics Adam S. Cheifetz, Joseph D. Feuerstein, 2017-11-09 This book is a concise yet comprehensive overview of the use of biologics for the treatment of Crohn’s disease and ulcerative colitis. The volume details how best to utilize these medications in order to optimize their efficacy and safety, as well as how to understand, recognize, and treat complications that may arise from using biologics to treat IBD. The text also focuses on new data, novel biologics, and biosimilars of this rapidly expanding field. Written by experts in the field, Treatment of Inflammatory Bowel Disease with Biologics is a valuable resource for gastroenterologists, allied health professionals, fellows, and trainees who treat patients with inflammatory bowel disease. |
Electrochemical Instruments Manufacturer / BioLogic
Trusted for over 40 years by academic and industrial organizations worldwide, BioLogic measurement instruments, including potentiostats, battery cyclers, impedance analyzers, …
Products - BioLogic
BioLogic manufactures a variety of robust and user-friendly, potentiostats for diverse applications, from single-channel potentiostats to bipotentiostats to multichannel potentiostats.
Your new potentiostat: unboxing, setup and settings for your
Mar 28, 2022 · This short, easy-to-follow video series will show you exactly how quickly and easily you can set up your BioLogic potentiostat, using the example of the BioLogic SP-150e (the …
Discover Battery Cyclers - BioLogic
BioLogic ® offers a comprehensive line-up of battery cyclers, designed to support every stage of the battery development cycle through two complementary instrument ranges: Premium and …
What is Electrochemical Impedance Spectroscopy (EIS)? - BioLogic
May 23, 2025 · A leader in Electrochemical Impedance Spectroscopy (EIS) technologies, BioLogic strives to place EIS within every researcher's reach, by making it available on all of …
Battery Cycler brochure - BioLogic
May 19, 2025 · The MPG-200 series is a high-end battery testing system made up of two core configurations. The MPG-2 features 16 independent channels at 100 mA, whereas the MPG …
Discover Potentiostat / Galvanostat - BioLogic
BioLogic potentiostats/galvanostats are designed with modularity in mind, offering a wide range of configurations and optional add-ons and accessories that can be tailored to meet your specific …
Overview: Spectrometer solutions - BioLogic
Details of BioLogic's spectrometer solutions: circular dichroism, High throughput CD Microplate spectropolarimeters and pump-probe spectrometers
VSP-3e Potentiostat - BioLogic
Energy-specific functionality unique to BioLogic includes: Fast CCCV shift (constant current, constant voltage) Stack mode (follow individual elements in the pack) BCD (Battery capacity …
EC-Lab® OEM - BioLogic
This package offers an array of tools that enable seamless integration with proprietary software, giving users precise control over their BioLogic Potentiostat/Galvanostat instruments. Key …
Treatment of ankylosing spondylitis with TNFα inhibitors …
known about the eect of biologic therapy in ankylosing spondylitis on the course of depression and the pathways of tryptophan metabolism (Rani et al. 2022). Already in 1964, attention was …
Global research trends in biological therapy for ankylosing …
Jan 15, 2025 · Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and pelvic bones. Recently, many researchers have confirmed that biological therapy is …
Long-term efficacy and safety of secukinumab 150 mg in …
of therapy. What does this study add? ... biologic-naïve subjects and for those patients who ... years in patients with ankylosing spondylitis (aS; MeaSUre 1 extension trial (nct01863732)). …
Persistence, Discontinuation, and Switching Patterns of
not remain on the index therapy 2 year post initiation. Funding: Eli Lilly and Company. Keywords: Ankylosing spondylitis; Persistence; Treatment patterns INTRODUCTION Ankylosing …
Ankylosing spondylitis: etiology, pathogenesis, and …
Ankylosing spondylitis (AS), a common type of spondyloarthropathy, is a chronic inflammatory autoimmune disease that mainly affects spine joints, causing severe, chronic pain; additionally, …
Pleural Tuberculosis following Infliximab Therapy for …
Ankylosing spondylitis is a spondyloarthropathy seen commonly among males. [1] Tumor necrosis factor‑alpha (TNF‑α) inhibitor is the drug of choice. Opportunistic infections following therapy …
Biologic therapy for axial SpA - National Axial …
spondylitis. Ankylosing Spondylitis (sometimes also called radiographic axial SpA) Where there are changes to the sacroiliac joints or the spine that can be seen ... Biologic therapy works to …
Biologic therapy and spinal radiographic progression in …
assessed by the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS), in patients with ankylosing spondylitis (AS) or nonradiographic axial spondyloarthritis (nr-axSpA) treated with …
Predicting the outcome of ankylosing spondylitis therapy
Predicting the outcome of ankylosing spondylitis therapy
POLICY PRIOR AUTHORIZATION - vivahealth.com
Ankylosing spondylitis, for reducing signs and symptoms in patients with active disease. ... However, there are situations where initial therapy with a biologic may be preferred over other …
UREQA2: Ankylosing Spondylitis: Appropriate …
Measure Title Ankylosing Spondylitis: Appropriate Pharmacologic Therapy Measure Description Percentage of patients aged 18 years and older with a first diagnosis of ankylosing spondylitis …
346 Thursday, 15 June 2017 Scientific Abstracts
Background: For patients with active ankylosing spondylitis (AS), biologic therapy has been shown to be an effective treatment option. Physicians treating patients with biologic therapy …
Persistence to Biologic Therapy Among Patients With …
Oct 27, 2021 · : ankylosing spondylitis, biologic therapy, disease-modifying antirheumatic drugs, medication persistence. This study received financial assistance from Janssen-Cilag Pty …
DOI: 10.1515/rjim-2017-0001 - ResearchGate
inflammatory involvement between patients with ankylosing spondylitis and those with IBD gave rise to the supposition that anti-TNF α therapy can decrease the intestinal inflammation in
The predictability of ASDAS on drug survival in patients with ...
in patients with ankylosing spondylitis on biologic therapy: data from the KOBIO registry Jinhyun Kim, Min Jung Kim, Geun Young Oh, Sun Kyung Lee, Taeeun Kim and Kichul Shin Abstract …
Changes in MiRNA-5196 expression as a potential biomarker …
p = 0.086) upon biologic therapy treatment. Finding novel biomarkers, including miRNA-5196 which allow to predict and monitor anti-TNF-α response, would be of clinical value especially …
Biologics and Ankylosing Spondylitis - National Axial …
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (nice.org.uk) ... inhibitors, which are the most commonly used …
Simponi ARIA® (golimumab)
Oct 3, 2024 · Ankylosing Spondylitis (AS) 7,24,28 Disease response as indicated by improvement in signs and symptoms compared to baseline such as total back pain, physical function, …
Changes in Tumor Necrosis Factor Inhibitor Drug Survival in …
To study changes in retention of first biologic disease-modifying antirheumatic drug (DMARD) therapy over a period of 15 years in an inception cohort of patients with rheumatoid arthritis …
Persistence to Biologic Therapy Among Patients With …
Oct 27, 2021 · : ankylosing spondylitis, biologic therapy, disease-modifying antirheumatic drugs, medication persistence. This study received financial assistance from Janssen-Cilag Pty …
Physiotherapy and rehabilitation in ankylosing spondylitis: is …
580 Int. J. Clin. Rheumatol. (2013) 8(5) utue iene ou REVIEW Akgul iliç ili zomen Physiotherapy & rehabilitation in ankylosing spondylitis REVIEW fitness. Exercises for patients with AS are …
Cost-effectiveness of secukinumab compared to other …
Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory disease that affects ... were naïve to biologic therapy were considered for the base-case analysis. For an alternate analysis, …
RECENT MAJOR CHANGES
inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. (1.6) RINVOQ is indicated for the treatment of adults with active non-radiographic …
Differences in biologics for treating ankylosing spondylitis: …
sion in the prescription patterns of biologic drugs for such disease. Head to head randomized con-trolled trials (RCTs) would require a large patient sample size in order to identify differences in …
Influence of biologic therapy on return to work in people …
KEY WORDS: Ankylosing spondylitis, Biologic therapy, Anti-TNF, Work, Socioeconomic, Employment, Work disability. Background The physical features and symptoms of AS are well …
Persistence to Biologic Therapy Among Patients With …
: ankylosing spondylitis, biologic therapy, disease-modifying antirheumatic drugs, medication persistence. This study received financial assistance from Janssen-Cilag Pty Limited, Australia. …
HIGHLIGHTS OF PRESCRIBING INFORMATION RINVOQ is not …
RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. (1.6) Limitations of Use …
TNF-alpha inhibitors for ankylosing spondylitis and non
Conventional therapy for ankylosing spondylitis and non-radiographic axial spondyloarthritis includes non-steroidal anti-inflammatory drugs and physiotherapy. Tumour necrosis factor …
SARAA recommendations for biologic use July 2019 Apr 2020 …
(tsDMARDs), all collectively known as biologic therapy or biologics, are important advances in the treatment of several rheumatic diseases, including rheumatoid arthritis (RA), ankylosing …
OHP PA Criteria: JAK Inhibitors - colpachealth.org
Ankylosing Spondylitis and Axial Spondyloarthritis Initial riteria If yes If no 1. Renewal Is the member transitioning to the requested treatment from a different biologic product (i.e. …
Etoricoxib in ankylosing spondylitis: is there a role for active ...
Consecutive patients with axial AS refractory to traditional NSAID eligible for anti-TNF-α therapy were selected. The primary outcomes were the rate of patients with good clinical response (not …
biologic registry analysis of Czech ATTRA ankylosing …
analysis of Czech ATTRA ankylosing spondylitis biologic registry Jan Tužil, Tomáš Mlčoch, Jitka Jirčíková, Jakub Závada, Lucie Nekvindová, ... Biological Therapy, DOI: 10.1080/14712598. ...
Humira (adalimumab) Abrilada* (adalimumab-afzb) Hulio
Humira and Amjevita can be used alone or in combination with non-biologic DMARDs. Ankylosing Spondylitis (AS) – Humira and its biosimilars are indicated for reducing signs and symptoms in …
Infliximab: An Unbranded Biologic Option From Johnson
An unbranded biologic is NOT a biosimilar FDA = US Food and Drug Administration. Brand-Name Biologic1 Unbranded Biologic2 Biosimilar1,3 Approved based on a full complement of safety …
CADTH Canadian Drug Expert Committee Recommendation
Reimburse in a manner similar to other interleukin-17 (IL-17) inhibitors for the treatment of ankylosing spondylitis. Pricing Conditions Ixekizumab should provide cost savings for drug …
Biologic Treatments: A Paradigm Shift in Medicine - aaom.com
Novartis, Janssen, Eli Lilly, UCB Ankylosing spondylitis Research (Clinical Trials) Janssen 2002-2004 ASSERT (infliximab) Ankylosing spondylitis 2006-2011 CNTO148 (golimumab SQ) …
Ankylosing spondylitis: Understanding the causes, …
Ankylosing spondylitis (AS) is a chronic inflammatory condition that primarily affects the spine and ... are often prescribed as first-line therapy to reduce pain and inflammation. ... disease …
Impact of clinical subtype and sex on first-line biologic …
Impact of clinical subtype and sex on first-line biologic therapy discontinuation in axial spondyloarthritis Patricia Remalante-Rayco1,2, Emmanuel S Baja2,3, Zeynep Baskurt4, ...
Disease Activity Cutoff Values in Initiating Tumor Necrosis …
ankylosing spondylitis (AS) recommend a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) level of disease activity of ≥ 4 to initiate treatment with biologics. ... benefit from …
ANKYLOSING SPONDYLITIS: A REVIEW - European Medical …
Ankylosing spondylitis is a chronic autoimmune inflammatory condition belonging to the ... favourable response to biologic therapy and can help to differentiate from mechanical causes …
BIOLOGIC AND IMMUNOLOGICAL AGENTS - INJECTION
Section A. Ankylosing Spondylitis (AS): Criteria for initial therapy:Biologic and Immunological Agents is considered medically necessary and will be approved when ALL of the following …
Upadacitinib (RINVOQ) in Axial Spondyloarthritis National …
• Upadacitinib is the second Janus kinase inhibitor (JAKI) approved for ankylosing spondylitis (AS; aka radiographic axial spondyloarthritis [r -axSpA]) and the first JAKI and targeted synthetic …
Colombian Association of Rheumatology. Consensus on
arthritis, ankylosing spondylitis, and psoriatic ... approximately twenty years, biologic therapy (BT) has been considered a follow-up therapy after conventional dis-ease modifying antirheumatic …
SPECIALTY GUIDELINE MANAGEMENT - nhpri.org
C. Ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) 1. Authorization of 12 months may be granted for adult members who have previously received a …
Simponi/Simponi Aria (golimumab) - Molina Healthcare
Drug and Biologic Coverage Criteria . Original Effective Date: 09/01/2013 Current Effective Date: 1. 2 / 06 ... Active Psoriatic Arthritis, Active Ankylosing Spondylitis, Ulcerative colitis (UC), Non …
Double Glomerulonephritis in a Patient with Ankylosing …
Ankylosing Spondylitis Disease Activity Index (BASDAI) 6,1. Bath Ankylosing Spondylitis Functional Index (BASFI): 4,9. Global Health 70. In January 2017 there is the first evidence of …
Treatment of Ankylosing Spondylitis - The Journal of …
Treatment of Ankylosing Spondylitis DANIEL O. CLEGG INTRODUCTION Ankylosing spondylitis (AS) is an inflammatory condi-tion whose main clinical feature is inflammatory back pain …
Therapy of ankylosing spondylitis and other …
biologic therapy is safe. Keywords: ankylosing spondylitis, anti-TNF-α therapy, conventional and innovative treatment, psoriatic arthritis Review Therapy of ankylosing spondylitis and other …
NICE TA implementation guidance – Biologics for ankylosing …
Conventional therapy for AS and nrAxSpA includes non-steroidal anti-inflammatory drugs (NSAIDs) and physiotherapy. ... ankylosing spondylitis, but it is the sixth biologic to be licensed …
Assessment of quality of life and clinical status in active …
Ankylosing Spondylitis Disease Activity Index (BAS-DAI), Bath Ankylosing Spondylitis Functional Index (BASFI) and Short Form Health Survey (SF-36) v.2. Results: The applied physical …
